Compound vs. brand-name GLP-1s: what the evidence shows

What did @michellesays actually say?

She claims that compounded tirzepatide at 15 mg felt significantly less effective for her than brand-name Zepbound at 10 mg or even 12.5 mg. Her evidence is personal: she rotated between compound and name-brand multiple times and consistently felt stronger appetite suppression on Zepbound. She's careful to say "I'm not knocking compounds" and frames this explicitly as her own experience, not a universal finding.

She also touches on the prior authorization process, suggesting her denials may stem from her doctor not writing thorough enough appeals, and mentions that Zepbound vials at $500/month are about $150 cheaper than what she currently pays with a coupon for the auto-injector pen.

Does the science back this up?

Here's the uncomfortable truth: the data on compounded GLP-1 consistency is genuinely thin, and regulators have noticed. The FDA does not approve compounded drugs for safety or efficacy, which means potency verification is left to individual pharmacies.

A 2023 analysis published by the U.S. Pharmacopeia documented that compounded semaglutide preparations showed variable concentrations depending on the compounding facility. Similar systematic data for compounded tirzepatide is essentially nonexistent in peer-reviewed literature as of early 2025. What we do know comes from the FDA's own 503B outsourcing facility inspections, which have flagged sterility and labeling issues at a non-trivial number of facilities. The agency issued warnings specifically about tirzepatide compounding in 2024, noting concerns about dosing accuracy and the use of salt forms (tirzepatide acetate or other variants) instead of the base molecule used in Zepbound. If a pharmacy was compounding a salt form rather than the free-base peptide, bioavailability could differ in ways that aren't obvious from the label. That is a plausible, if unproven, mechanism for what Michelle describes.

What did they get wrong (or right)?

She gets credit for intellectual honesty. She repeatedly acknowledges that "logically it should be the same exact thing" and resists the urge to make a sweeping claim that all compounded tirzepatide is inferior. That kind of self-awareness is rare in this content category.

Where she's on shakier ground: her comparison methodology is about as uncontrolled as it gets. She switched doses, waited varying time periods between trials, had medications of different ages in her fridge, and was simultaneously navigating PCOS-related hormonal variability. Any of those factors could explain perceived differences in suppression. The "10 mg that had been in the fridge for a while" feeling more effective than fresh 15 mg compound is the kind of anecdote that should raise eyebrows, not confirm a hypothesis. Peptide degradation over time would typically reduce potency, not increase it, which makes that data point hard to interpret.

Her comments on prior authorization are reasonable and accurate in spirit. Insurance appeals are more effective when physicians document clinical necessity in detail, and the observation that busy prescribers may submit thin appeals is supported by real-world access research (Chua et al., 2022, JAMA Internal Medicine).

What should you actually know?

The FDA declared both semaglutide and tirzepatide no longer in shortage in 2024, which means 503A and 503B compounding pharmacies are legally required to stop producing these drugs. That regulatory landscape directly affects anyone relying on compounded GLP-1s. Some pharmacies are still operating under legal challenges as of early 2025, so availability is in flux.

On the question of whether compounded and brand-name tirzepatide are equivalent: they are not automatically equivalent. Compounded drugs are not FDA-approved versions of the branded product. The active ingredient may be identical in some formulations, but purity, excipients, and concentration accuracy are not independently verified by the FDA. That does not mean compounded versions don't work for many people. Large numbers of patients have used them without obvious issues. But it does mean individual variation in response, like what Michelle describes, has a plausible pharmacological explanation even if her specific self-experiment can't prove it.

If you're on compounded tirzepatide and feel it's less effective, that's worth raising with your prescriber. It's not something to diagnose from a TikTok comment section.

Bottom line on her prior authorization situation

Her instinct to review the insurer's specific criteria before the next appeal is correct. Most GLP-1 coverage denials for obesity indications hinge on BMI documentation, comorbidity coding, and documented prior treatment attempts. If her physician's notes don't explicitly reference those criteria in the appeal language, the denial is almost automatic regardless of clinical appropriateness. Patients are allowed to request detailed denial letters and provide their own supporting documentation alongside physician letters, though physician-authored appeals carry more weight with most payers.